Welcome to our dedicated page for AXON ENTERPRISE SEC filings (Ticker: AXON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AXON ENTERPRISE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AXON ENTERPRISE's regulatory disclosures and financial reporting.
Brittany Bagley, COO & CFO of Axon Enterprise (AXON), reported sales and tax-withholdings of company common stock in late September 2025. Restricted stock units vested and 14,430 shares were withheld to cover taxes on September 26, 2025. Under a Rule 10b5-1 trading plan adopted June 16, 2025, Bagley sold additional shares on September 29, 2025, in multiple trades: 566, 1,025, 205, 300, 1,829 and 1,075 shares at weighted-average prices ranging from about $709.80 to $716.70, with the reported weighted prices shown per line. After these transactions the filing shows Bagley beneficially owning 93,592 shares.
AXON ENTERPRISE, INC. Form 144 notice: The filer reports a proposed sale of 5,000 shares of Common stock through Morgan Stanley Smith Barney LLC on 09/29/2025, with an aggregate market value reported at $3,544,200.00 and a stated number of outstanding shares of 78,504,440. The securities were acquired as Restricted Stock Units on 09/26/2025 from the issuer and payment/consideration is listed as N/A. The filing also discloses a prior sale by Brittany Bagley of 870 shares on 09/15/2025 for gross proceeds of $672,724.89. Broker address and signature/attestation language are included in the notice.
Jennifer H. Mak, Chief Accounting Officer of Axon Enterprise, Inc. (AXON), reported a sale of 77 shares of common stock on 09/15/2025. The sale was effected under a Rule 10b5-1 trading plan adopted March 14, 2025, and related to shares issued upon settlement of vested restricted stock units. The reported sale price was $760 per share. After the transaction, Ms. Mak beneficially owned 15,003 shares directly. The Form 4 was signed by an attorney-in-fact on her behalf.
Brittany Bagley, identified as AXON's COO & CFO, reported a sale of 870 shares of AXON common stock on 09/15/2025 at a price of $773.247 per share. After the transaction she beneficially owned 113,022 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Jeri Williams, a director of Axon Enterprise, Inc. (AXON), reported a sale of company stock on 09/11/2025. The Form 4 shows she disposed of 100 shares of Common Stock in one or more trades at a weighted average price of $752.5434 per share, with execution prices ranging from $752.50 to $752.61. Following the reported transaction, the filing lists 1,416 shares beneficially owned by Ms. Williams in a direct ownership form. The filing was signed on her behalf by an attorney-in-fact, Isaiah Fields.
Form 144 filed for AXON ENTERPRISE, INC. The notice reports a proposed sale of 870 shares of common stock through Morgan Stanley Smith Barney LLC on 09/15/2025 on NASDAQ with an aggregate market value of $672,724.89. Total shares outstanding listed are 78,504,440. The 870 shares consist of 143 shares acquired on 06/26/2024 and 727 shares acquired on 08/13/2025, both from restricted stock vesting under a registered plan; payments are marked as Not Applicable. The filer states there have been no sales by the person in the past three months and includes the standard representation that no undisclosed material adverse information is known.
Axon Enterprise, Inc. (AXON) filed a Form 144 notifying a proposed sale of 100 shares of common stock through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $75,254.34. The filing lists 78,504,440 shares outstanding for the issuer and an approximate sale date of 09/11/2025 on NASDAQ. The shares were acquired on 05/13/2024 as restricted stock vesting under a registered plan and payment was recorded on the same date. The filer reported no securities sold in the past three months and included the standard Rule 144 representation regarding absence of undisclosed material adverse information.
Axon CEO and director Patrick W. Smith reported sales of 10,000 shares of Axon Enterprise, Inc. (AXON) common stock executed on 09/08/2025 under a Rule 10b5-1 trading plan. The Form 4 lists 13 separate sell transactions that reduced his direct holdings to 3,043,982 shares following the sales. The filings state the trades were effected pursuant to a 10b5-1 plan adopted May 12, 2025, and executed in multiple trades with prices reported as weighted averages for each lot, with executed trade prices ranging from $734.22 to $749.00 per share. The Form 4 was signed on behalf of Mr. Smith by an attorney-in-fact.
Axon Enterprise, Inc. insider notice reports a proposed sale of 10,000 common shares through UBS Financial Services on Nasdaq with an aggregate market value of $7,436,415, dated for sale on 09/08/2025. The same block of 10,000 shares was acquired by option exercise on 11/15/2021 and paid in cash on that date. The filer also reported a prior sale of 10,000 common shares by Patrick W. Smith on 08/11/2025 for $8,312,887 in gross proceeds. The filing omits the issuer's address and the filing individual's CIK/CCC details.
Hadi Partovi, a director of Axon Enterprise, Inc. (AXON), reported a non-derivative transaction on 08/29/2025 reflecting a grant of 100 restricted stock units (RSUs) under the Axon Second Amended and Restated 2022 Stock Incentive Plan that vested in full on the grant date. The filing shows the RSUs were issued at a $0 price and that Mr. Partovi beneficially owned 238,038 shares following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Partovi on 09/03/2025. The filing indicates the reporter is a director and the form was filed by one reporting person.